Roginolisib

罗吉诺利

Roginolisib

R655604-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC 50 of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases In Vitro Roginolisib (0-10 μM; 1 hours) completely abolished BCR-induced pAkt in Ramos B cells in a concentration-dependent manner with IC 50 values of 280?nM. Roginolisib inhibits B cell proliferation in a concentration-dependent manner with an IC 50 of 48?nM. Roginolisib blocks BCR- and TCR-mediated responses in lymphocytes and TLR-induced IFNα by pDC in human primary cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: B cells Concentration: 0-10 μM Incubation Time: 1 hour Result: Inhibited B cell proliferation in a concentration-dependent manner with an IC 50 of 48 nM. In Vivo Roginolisib (6.6-66 mg/kg; daily from week 2 to 10) ameliorates disease manifestations in a murine SLE model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NZB/W F1 female mice Dosage: 6.6, 22, or 66 mg/kg Administration: Oral; starting at week 2 post ADV-IFNα delivery, once daily at 10 weeks Result: Significantly reduced proteinuria incidence and severity in a dose-dependent manner. IC50& Target:PI3Kδ 145 nM (IC 50 ) PI3Kα 18500 nM (IC 50 ) PI3Kβ 2850 nM (IC 50 )

Roginolisib（MSC2360844；IOA-244）是一种强效、口服活性和选择性 PI3Kδ 抑制剂，IC 50 为 145 nM。Roginolisib 对另外 278 种激酶具有高度选择性。

1305267-37-1(DMSO)

C26H27FN4O5S

526.58 g/mol

C1COCCN1CC2=CC=C(C=C2)N3C4=C(CS(=O)(=O)C5=C4C=CC=C5F)C(=N3)C(=O)N6CCOCC6